Drugs / phage therapy
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT06814756 | Mar 2025 → Mar 2026 overdue | periprosthetic joint infection | University of Calgary | Active not recruiting | No outcome recorded |
| Comparator or background therapy1 trial | ||||||
| Phase 1/2 | NCT06409819 Comparator | Jun 2025 → Oct 2026 expected | urinary tract infection | University of California, San Diego | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | phage therapy | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06409819 ↗ |
| Modality | Other / unclassified | “phage therapy will consist of a combination of three lytic phages” NCT06409819 ↗ |
| Route | Intravenous | “will be administered intravenously twice daily for 7 days” NCT06409819 ↗ |